These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12669379)

  • 1. Effect of tissue penetration on AmBisome efficacy.
    Adler-Moore J; Proffitt RT
    Curr Opin Investig Drugs; 2003 Feb; 4(2):179-85. PubMed ID: 12669379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B: clinical experience and perspectives.
    Gibbs WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
    Azanza Perea JR; Barberán J
    Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
    Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
    J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
    Shah T; Lai WK; Gow P; Leeming J; Mutimer D
    Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New dosing strategies for liposomal amphotericin B in high-risk patients.
    Ellis M
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():55-64. PubMed ID: 18430130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
    Bellmann R; Cleary JD; Sterba J
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment.
    Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Mahi L; Deray G
    Nephrol Dial Transplant; 2007 Oct; 22(10):3090-1. PubMed ID: 17595189
    [No Abstract]   [Full Text] [Related]  

  • 12. AmBisome (liposomal amphotericin B): a comparative review.
    Boswell GW; Buell D; Bekersky I
    J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.
    Vogelsinger H; Weiler S; Djanani A; Kountchev J; Bellmann-Weiler R; Wiedermann CJ; Bellmann R
    J Antimicrob Chemother; 2006 Jun; 57(6):1153-60. PubMed ID: 16627591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)].
    Maniwa T; Yamamoto Y
    Nihon Yakurigaku Zasshi; 2007 Feb; 129(2):129-34. PubMed ID: 17299241
    [No Abstract]   [Full Text] [Related]  

  • 15. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.
    Townsend RW; Zutshi A; Bekersky I
    Drug Metab Dispos; 2001 May; 29(5):681-5. PubMed ID: 11302934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AmBisome today: expanding the perspectives on liposomal amphotericin B.
    Richardson M
    Acta Biomed; 2006; 77 Suppl 2():3-4. PubMed ID: 16918058
    [No Abstract]   [Full Text] [Related]  

  • 17. Amphotericin B lipid preparations: what are the differences?
    Adler-Moore JP; Proffitt RT
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B.
    Capilla J; Mayayo E; Serena C; Pastor FJ; Guarro J
    J Antimicrob Chemother; 2004 Dec; 54(6):1092-5. PubMed ID: 15509616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B, AmBisome.
    Hay RJ
    J Infect; 1994 May; 28 Suppl 1():35-43. PubMed ID: 8077689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of amphotericin B and its derivatives].
    Vetkina IF
    Antibiot Khimioter; 1991 Apr; 36(4):36-8. PubMed ID: 1892433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.